Table 2.
Indinavir concentration in plasma and lymph node tissuea in HIV-infected macaques treated with either oral soluble indinavirb or subcutaneous lipid-associated indinavirc at a normalized dose of 25 mg/kg. Lymph node drug concentration is expressed as lymph node-to-plasma ratio
| Animal ID | Plasma (ng/mL) | Lymph node:plasma ratio (indinavir)
|
|||
|---|---|---|---|---|---|
| Inguinal | Axillary | Mesenteric | Ileocecal | ||
| Free indinavir (PO) | |||||
| 94079 | 9.8 | 0.03 | 0.01 | – | – |
| 94094 | 5.2 | 0.01 | 0.02 | – | – |
| 94096 | 39.8 | 0.01 | <0.01 | – | – |
| Lipid-associated indinavir (SC) | |||||
| M98165 | 79.5 | 3.43 | 2.46 | 4.99 | 32.55 |
| J98328 | 52.0 | 6.27 | 2.48 | 16.26 | 7.01 |
For lymph node drug concentration, 1–10 mg of lymph node tissue was homogenized and drug was extracted as described previously [17]
Free drug was administered orally in solution at a dose of 25 mg/kg, and samples were collected 2–4 h after administration. Mesenteric and ileocecal lymph nodes were not sampled
Lipid-associated drug was administered subcutaneously at 10 mg/kg (data normalized to a dose of 25 mg/kg for comparison), and samples were collected 26–28 h after administration